Citation Tools

Download PDFPDF

Short report
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Download to a citation manager

Cite this article as:
Alessi JV, Ricciuti B, Jiménez-Aguilar E, et al
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status